Dr John Buscombe
British Nuclear Medicine Society
Dr John Buscombe is the President of the British Nuclear Medicine Society and works as a Consultant Physician in Nuclear Medicine in Cambridge.
Theranostics in prostate cancer new or false dawn
Over the past 2 years new imaging and therapeutic options using radiolabelled prostate specific membrane antigen have been developed which enable us to see disease which cannot be found by other methods with gallium-68 PSMA PET-CT. Newer work has linked this to targeted radionuclide therapy using beta and alpha emitter labelled PSMA is previously untreatable metastatic prostate cancer which is being actively developed.
EVEN MORE SEMINARS
Estevao Mauricio Bagi Royal Brompton & Harefield Hospitals Specialist Care
Cardiac PET-CT : Rubidium-82 Myocardium Perfusion & 18F-FDG Cardiac Sarcoidosis
Dr Sam Hare Royal Free London NHS Foundation Trust
How I evaluate lung lesions for CT-guided biopsy?
Dr Arjun Nair The Harley Street Clinic (Part of HCA healthcare UK)
Advance Technologies in Diagnostics
Glenn Flux Royal Marsden / Institute of Cancer Research
The emergence and resurgence of radiotherapeutics for cancer treatment
Mohamed Torky Hospital Germans Trias i pujol. Barcelona. Spain
The seminar will present the preliminary results of a study included patients with peripheral lung lesions suspicious for lung cancer. Trans-bronchial